|
1
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Okamoto I, Morita S, Tashiro N, Imamura F,
Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K and Fukuoka M:
Real-world treatment and outcomes in EGFR mutation-positive
non-small cell lung cancer: Long-term follow-up of a large patient
cohort. Lung Cancer. 117:14–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nosaki K, Satouchi M, Kurata T, Yoshida T,
Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N,
et al: Re-biopsy status among non-small cell lung cancer patients
in Japan: A retrospective study. Lung Cancer. 101:1–8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chouaid C, Dujon C, Do P, Monnet I,
Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, et
al: Feasibility and clinical impact of re-biopsy in advanced
non-small-cell lung cancer: A prospective multicenter study in a
real-world setting (GFPC study 12-01). Lung Cancer. 86:170–173.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim TO, Oh IJ, Kho BG, Park HY, Chang JS,
Park CK, Shin HJ, Lim JH, Kwon YS, Kim YI, et al: Feasibility of
re-biopsy and EGFR mutation analysis in patients with non-small
cell lung cancer. Thorac Cancer. 9:856–864. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oxnard GR, Thress KS, Alden RS, Lawrance
R, Paweletz CP, Cantarini M, Yang JC, Barrett JC and Jänne PA:
Association between plasma genotyping and outcomes of treatment
with osimertinib (AZD9291) in advanced non-small-cell lung cancer.
J Clin Oncol. 34:3375–3382. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Husain H, Melnikova VO, Kosco K, Woodward
B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, et
al: Monitoring daily dynamics of early tumor response to targeted
therapy by detecting circulating tumor DNA in urine. Clin Cancer
Res. 23:4716–4723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carpagnano GE, Foschino-Barbaro MP, Mulé
G, Resta O, Tommasi S, Mangia A, Carpagnano F, Stea G, Susca A, Di
Gioia G, et al: 3P microsatellite alterations in exhaled breath
condensate from patients with non-small cell lung cancer. Am J
Respir Crit Care Med. 172:738–744. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Youssef O, Knuuttila A, Piirilä P, Böhling
T, Sarhadi V and Knuutila S: Hotspot mutations detectable by
next-generation sequencing in exhaled breath condensates from
patients with lung cancer. Anticancer Res. 38:5627–5634. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smyth RJ, Toomey SM, Sartori A, O'Hanrahan
E, Cuffe SD, Breathnach OS, Morgan RK and Hennessy BT: Brief report
on the detection of the EGFR T790M mutation in exhaled breath
condensate from lung cancer patients. J Thorac Oncol. 13:1213–1216.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang D, Takigawa N, Ochi N, Tanimoto Y,
Noujima D, Chen YY, Tanimoto M and Kiura K: Detection of the EGFR
mutation in exhaled breath condensate from a heavy smoker with
squamous cell carcinoma of the lung. Lung Cancer. 73:379–380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sacher AG, Paweletz C, Dahlberg SE, Alden
RS, O'Connell A, Feeney N, Mach SL, Jänne PA and Oxnard GR:
Prospective validation of rapid plasma genotyping for the detection
of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol.
2:1014–1022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzawa K, Yamamoto H, Ohashi K, Hashida S,
Tomida S, Kubo T, Maki Y, Soh J, Tsukuda K, Kiura K, et al: Optimal
method for quantitative detection of plasma EGFR T790M mutation
using droplet digital PCR system. Oncol Rep. 37:3100–3106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Senoo S, Ohashi K, Nishii K, Hara N, Kano
H, Ninomiya K, Maeda Y and Kiura K: Osimertinib depletes EGFR T790M
in the spinal fluid of patients with carcinomatous meningitis of
lung adenocarcinoma harboring de novo EGFR T790M. J Thorac Oncol.
13:e140–e142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (eighth) edition of the TNM Classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ohashi K, Sequist LV, Arcila ME, Moran T,
Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et
al: Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS,
NRAS, or MEK1. Proc Natl Acad Sci USA. 109:E2127–E2133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ogino A, Kitao H, Hirano S, Uchida A,
Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K and Tanimoto M:
Emergence of epidermal growth factor receptor T790M mutation during
chronic exposure to gefitinib in a non-small cell lung cancer cell
line. Cancer Res. 67:7807–7814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohashi K, Maruvka YE, Michor F and Pao W:
Epidermal growth factor receptor tyrosine kinase
inhibitor-resistant disease. J Clin Oncol. 31:1070–1080. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee K, Kim Y, Jung HA, Lee SH, Ahn JS, Ahn
MJ, Park K, Choi YL and Sun JM: Repeat biopsy procedures and T790M
rates after afatinib, gefitinib, or erlotinib therapy in patients
with lung cancer. Lung Cancer. 130:87–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seto T, Nogami N, Yamamoto N, Atagi S,
Tashiro N, Yoshimura Y, Yabuki Y and Saka H: Real-world EGFR T790M
testing in advanced non-small-cell lung Cancer: A prospective
observational study in Japan. Oncol Ther. 6:203–215. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ichihara E, Hotta K, Kubo T, Higashionna
T, Ninomiya K, Ohashi K, Tabata M, Maeda Y and Kiura K: Clinical
significance of repeat rebiopsy in detecting the EGFR T790M
secondary mutation in patients with non-small cell lung cancer.
Oncotarget. 9:29525–29531. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vogelstein B and Kinzler KW: Digital PCR.
Proc Natl Acad Sci USA. 96:9236–9241. 1999. View Article : Google Scholar : PubMed/NCBI
|
